Regenerative medicine is going from strength to strength, with over 50 RMAT designations in the US to date, successful development of autologous stem cell treatments and renewed interest from the aesthetics industry. Gene therapies continue to show promise and inch closer to adoption. It is an incredibly exciting time to be a part of the growing longevity community with cell & gene pioneers expanding age-related solutions such as novel neural stem cell therapy, muscle tissue constructs and gene modifiers for macular degeneration.
Meanwhile longevity science is at a critical moment in time. In the wake of the COVID-19 pandemic investors, regulators and the medical community have woken up to the promise of ageing science and its potential to completely change how we prevent and treat disease. Advanced analytical tools are driving huge strides in our understanding of ageing biology and potential targets, and a number of high-profile fund raises are driving investor interest in the space.
Regenerative medicine and longevity therapeutics have both come a long way in recent years and set for the next decade of innovation, particularly with both gaining from parallel advancements in ageing science. The deeper understanding in cellular senescence, identification of aging genes, tissue engineering constructs and advancements in RNA modulation are all allowing longevity science and cell & gene therapies space to learn and innovate together.
The Longevity Leaders World Congress brings the world’s most prominent regenerative medicine and longevity scientists together, presenting the new research, responsible drug development, novel therapies and commercialisation to target age-related diseases. We’d love you to join us!
“A tremendous event!”
Omair Ahmed, Founder & Chief Product Officer, Neurometry
Longevity therapeutics market expected to reach $524 million by 2027
More than £1 billion invested in longevity biotech to date
3000+ longevity and regenerative medicine biotechs worldwide
Cell and gene therapy market is forecast to reach $45 billion by 2028
£8.25 billion raised by cell and gene therapy companies in 2020
54 RMAT (Regenerative Medicine Advanced Therapy) designations to date from the FDA
5000+ investors committing to longevity and regenerative medicine
More than 13,330 active cell therapy trials ongoing
667 active clinical trials for ageing as a disease worldwide